Uromigos-ASCO 2023-Kidney Cancer
Advertisement
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.